Key result
Imidapril achieves ~75% maximal ACE inhibition with consistent blood pressure reduction acutely and at steady state.
Why the study?
The pharmacokinetic profile and pharmacodynamic effects of imidapril after a single dose and at steady state in hypertensive patients were not well characterized.
Answers are grounded in this paper and cite their sources.
Similar AUC after single dose and 28-day therapy in 10 hypertensives; leaves open confirmation in larger, diverse populations.
AIMS: To investigate the pharmacokinetic profile of the ACE-inhibitor imidapril in 10 hypertensive patients after a first single dose (10 mg) and after 28 days therapy with imidapril 10 mg once daily. METHODS: Cmax, tmax, t1/2 and AUC of imidapril and imidaprilat were obtained. ACE-activity and arterial blood pressure during imidapril were corrected by a preceding placebo-investigation. RESULTS: The AUC of imidapril was 140 (43 s.d.) ng ml(-1) h after the first dose and 123 (34 s.d.) ng ml(-1) h at steady state. AUC of the active moiety imidaprilat averaged 211 (101 s.d.) ng ml(-1) h after the first dose and 240 (55 s.d.) ng ml(-1) h at the steady state investigation. Maximal ACE-inhibition was 75% after the single dose as well as at steady state. ACE inhibition before drug intake at day 28 (i.e. trough) was 50%. The (placebo-corrected) maximal drop in diastolic blood pressure after imidapril was 22 mm Hg after the first dose and 25 mmHg at steady state. Exploratory analysis of imidaprilat plasma concentration vs effect profiles suggests a hyperbolic concentration effect relationship where data of the single dose contribute to the ascending part of an Emax-curve, whereas the plateau around Emax is maintained at steady state. CONCLUSIONS: In this group of hypertensive patients, the pharmacokinetic profile and the drop in ACE-activity as well as in blood pressure seen after a single dose of imidapril and at steady state were similar. The initial response to a test dose might therefore predict the response during chronic dosing.
No takes yet. Share an insight, caveat, or question.
Harder et al. (1998) studied Hypertension (n=10). Imidapril vs. Placebo was evaluated on Maximal ACE-inhibition. Imidapril daily yielded a similar maximal ACE-inhibition of 75% and placebo-corrected drop in diastolic blood pressure (22 vs 25 mm Hg) after a single dose and 28 days at steady state.
Synapse has enriched 10 related papers. Consider them for comparative context: